Cambridge, MA — January 27, 2026 — Leads & Copy — Vyome Holdings, Inc. (NASDAQ: HIND) has announced key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis of VT-1953, a clinical candidate for treating malignant fungating wounds (MFW).
The analysis was conducted by Destum Partners, Inc., a life sciences strategy and transaction advisory firm. MFW is a rare and devastating complication of advanced solid tumors that causes severe malodor, pain, and psychosocial distress.
Tom Filipczak, Managing Director and Partner at Destum Partners, stated that MFW represents one of the most severe and underserved conditions in oncology supportive care. He added that his team conducted rigorous primary and secondary research, including clinician interviews, epidemiology modeling, pricing benchmarking, and valuation analyses. Filipczak noted that the absence of approved therapies and the high unmet need make this indication a compelling clinical and commercial opportunity.
The assessment by Destum Partners estimates the total addressable pharmacologic market in the U.S. for MFW to be approximately USD 2.2 billion. A bottom-up commercial model projects peak annual net sales for VT-1953 at approximately USD 600 million. Using a risk-adjusted net present value (rNPV) methodology, the estimated U.S. asset value is projected to be USD 455 million after successful Phase 2 data, and is projected to approach USD 1 billion following successful Phase 3 completion.
Venkat Nelabhotla, Chief Executive Officer of Vyome, stated that the independent analysis reinforces their conviction in the potential of VT-1953. He added that they engaged a third-party consulting firm to conduct an unbiased assessment of the commercial opportunity for this program, where there are currently no FDA-approved drugs. Nelabhotla noted that Destum Partners’ conclusion around the total addressable market in the U.S., together with the modeled potential peak sales and significant post-Phase 3 potential valuation, provides important external validation as they seek to advance VT-1953 toward pivotal development.
The analysis by Destum Partners incorporated extensive secondary research, epidemiology modeling, competitive landscape evaluation, pricing benchmarking, and primary research interviews with key opinion leaders across oncology, palliative care, wound care, and hospice settings.
Vyome is focused on developing therapies for serious immuno-inflammatory and rare conditions. Destum Partners provides clients with customized solutions that unlock value and optimize decision-making.
Source: Vyome Holdings, Inc.
